ALKYLAMINE - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.4
| Stock Code | ALKYLAMINE | Market Cap | 8,071 Cr. | Current Price | 1,575 ₹ | High / Low | 2,449 ₹ |
| Stock P/E | 44.7 | Book Value | 282 ₹ | Dividend Yield | 0.63 % | ROCE | 18.7 % |
| ROE | 14.0 % | Face Value | 2.00 ₹ | DMA 50 | 1,628 ₹ | DMA 200 | 1,818 ₹ |
| Chg in FII Hold | 0.01 % | Chg in DII Hold | 0.13 % | PAT Qtr | 42.3 Cr. | PAT Prev Qtr | 42.9 Cr. |
| RSI | 48.9 | MACD | -9.78 | Volume | 37,133 | Avg Vol 1Wk | 56,094 |
| Low price | 1,507 ₹ | High price | 2,449 ₹ | PEG Ratio | -7.42 | Debt to equity | 0.00 |
| 52w Index | 7.26 % | Qtr Profit Var | -3.43 % | EPS | 35.3 ₹ | Industry PE | 27.4 |
📊 Analysis: ALKYLAMINE is trading at ₹1,575, below both its 50 DMA (₹1,628) and 200 DMA (₹1,818), reflecting short-term weakness. RSI at 48.9 indicates neutral momentum, while MACD (-9.78) shows bearish crossover. Intraday volume (37,133) is lower than the weekly average (56,094), suggesting limited participation. Fundamentals are decent with ROCE (18.7%) and ROE (14.0%), but quarterly PAT declined slightly (-3.43%) and valuation is stretched (P/E 44.7 vs industry 27.4, negative PEG ratio -7.42). Debt-free balance sheet adds stability, but intraday momentum remains weak.
💡 Optimal Buy Price: ₹1,560–1,565 if price consolidates near support.
🎯 Profit-Taking Levels: ₹1,595–1,605 (short-term resistance zone).
🛡️ Stop-Loss: ₹1,545 to protect against downside risk.
⏱️ Exit Strategy (if already holding): Exit if price fails to sustain above ₹1,595 with strong volume. Weak intraday momentum suggests booking profits early rather than holding for extended moves.
Positive
- ROCE (18.7%) and ROE (14.0%) show reasonable efficiency.
- Debt-to-equity ratio of 0.00 indicates a debt-free balance sheet.
- EPS of ₹35.3 supports earnings visibility.
- Stable institutional interest with slight increases in FII (+0.01%) and DII (+0.13%).
Limitation
- Trading below both 50 DMA and 200 DMA, showing bearish trend.
- Quarterly PAT declined from ₹42.9 Cr. to ₹42.3 Cr. (-3.43%).
- High P/E (44.7) compared to industry average (27.4).
- Negative PEG ratio (-7.42) indicates valuation concerns.
- Intraday volume below average, limiting momentum trades.
Company Negative News
- No major negative news reported, but earnings decline raises caution.
Company Positive News
- Debt-free balance sheet adds financial stability.
- EPS of ₹35.3 reflects steady profitability.
Industry
- Industry P/E at 27.4 indicates sector is moderately valued compared to ALKYLAMINE’s high valuation.
- Chemicals sector benefiting from industrial demand and export opportunities.
Conclusion
⚖️ ALKYLAMINE shows decent fundamentals but weak intraday momentum and stretched valuations. It is a cautious candidate for intraday trading with entry near ₹1,560–1,565 and profit-taking around ₹1,595–1,605. Traders should closely monitor volume and momentum indicators before committing to positions.
IntraDay Trade Rating: 3.8
📊 Analysis: ALKEM is trading at ₹5,642, slightly below its 50 DMA (₹5,656) but above its 200 DMA (₹5,438), reflecting mixed momentum. RSI at 48.2 indicates neutral positioning, while MACD (-6.34) shows mild bearish crossover. Intraday volume (79,440) is lower than the weekly average (1,06,635), suggesting reduced participation. Fundamentals remain strong with ROCE (19.5%), ROE (19.9%), and minimal debt-to-equity (0.06). Valuation is close to industry average (P/E 30.2 vs 29.1), supported by quarterly PAT growth (+12.8%). Short-term technicals show caution, but strong fundamentals make it moderately favorable for intraday trading.
💡 Optimal Buy Price: ₹5,620–5,630 if price consolidates near support.
🎯 Profit-Taking Levels: ₹5,690–5,710 (near 50 DMA resistance).
🛡️ Stop-Loss: ₹5,600 to protect against downside risk.
⏱️ Exit Strategy (if already holding): Exit if price fails to sustain above ₹5,690 with strong volume. Momentum indicators suggest limited upside, so profit booking should be considered near resistance levels to avoid reversal risk.
Positive
- Strong ROCE (19.5%) and ROE (19.9%) highlight efficient capital use.
- EPS of ₹204 reflects strong earnings power.
- Debt-to-equity ratio of 0.06 indicates a virtually debt-free balance sheet.
- Quarterly PAT growth from ₹610 Cr. to ₹724 Cr. (+12.8%).
- FII holding increased by 0.50%, showing foreign investor confidence.
Limitation
- Trading below 50 DMA indicates short-term weakness.
- MACD negative crossover suggests bearish momentum.
- Intraday volume lower than average, limiting momentum trades.
- DII holding decreased by 0.39%, showing reduced domestic support.
Company Negative News
- No major negative news reported, but short-term technical weakness persists.
Company Positive News
- Quarterly profit growth supports earnings momentum.
- Strong fundamentals with high ROCE, ROE, and EPS.
Industry
- Industry P/E at 29.1 indicates sector is moderately valued.
- Pharmaceutical sector benefiting from healthcare demand and expansion opportunities.
Conclusion
⚖️ ALKEM shows strong fundamentals but weak short-term technical momentum. It is a moderate candidate for intraday trading with entry near ₹5,620–5,630 and profit-taking around ₹5,690–5,710. Traders should closely monitor volume and momentum indicators before committing to positions.